Paracetamol/Kodein Evolan

Active Ingredient:: Paracetamol, Codeine Phosphate Hemihydrate
Origin:: EU

Paracetamol/Kodein Evolan (Paracetamol, Codeine Phosphate Hemihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Paracetamol, the active ingredient in Paracetamol/Kodein Evolan, is an analgesic presented as a combination tablet for oral use. It works together with codeine phosphate hemihydrate to relieve moderate to severe pain and reduce fever in adult patients, and is intended for short‑term management when non‑opioid therapy is insufficient.

GNH India supplies Paracetamol/Kodein Evolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Manufacturer / TM Owner

Evolan Pharma Ab

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Paracetamol/codeine phosphate is an analgesic combination used for pain management.

Mild to moderate acute pain: provides relief when non‑opioid analgesics alone are inadequate.
Post‑operative pain: helps control discomfort after surgical procedures.
Dental pain: reduces discomfort associated with dental extractions or procedures.
Short‑term severe musculoskeletal pain: used for brief relief of intense flare‑ups.

How It Works

Paracetamol reduces pain and fever by inhibiting central cyclooxygenase enzymes, decreasing prostaglandin synthesis in the brain. Codeine phosphate hemihydrate is a pro‑drug converted to morphine, which activates μ‑opioid receptors in the central nervous system, producing analgesia and a modest antitussive effect. The combined actions provide synergistic pain relief.

Side Effects

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel movements.
Dizziness: feeling light‑headed or unsteady.
Drowsiness: increased sleepiness.

Serious or Rare Side Effects

Respiratory depression: slowed breathing, especially at higher doses.
Severe allergic reaction: rash, swelling, or anaphylaxis.
Liver toxicity: elevated enzymes or hepatic injury, particularly with overdose.

Precautions & Warnings

Paracetamol/Kodein Evolan should be used only after assessing pain severity and patient history.

Hepatic impairment: avoid or use with caution in severe liver disease.
Elderly patients: monitor for increased sedation and falls.
Concomitant CNS depressants: do not combine with other opioids, benzodiazepines, or alcohol.
Dependence risk: watch for signs of misuse or addiction.
Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Paracetamol/Kodein Evolan may interact with several medicines.

Major Interactions (Avoid)

Other opioid analgesics: additive risk of respiratory depression.
Benzodiazepines: increased sedation and respiratory compromise.
Alcohol: enhances central nervous system depression.

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (e.g., fluoxetine): may raise codeine levels.
CYP3A4 inducers (e.g., rifampicin): may reduce codeine effectiveness.
Anticoagulants (e.g., warfarin): paracetamol can potentiate anticoagulant effect.

Frequently Asked Questions

Paracetamol/Kodein Evolan is an oral analgesic combination indicated for the short‑term relief of moderate to severe pain, such as post‑operative discomfort, dental pain, and acute musculoskeletal pain, as well as for reducing fever when non‑opioid options are insufficient.

Paracetamol acts centrally by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production in the brain, thereby reducing pain perception and fever. Codeine phosphate is metabolised to morphine, which binds to μ‑opioid receptors in the central nervous system, providing additional analgesic effect.

The specific dose and dosing interval are determined by the prescribing clinician based on the patient’s age, weight, pain severity, and overall health status. No universal dosing regimen is provided here; the prescriber will tailor therapy to each individual case.

Paracetamol is generally considered low risk in pregnancy when used at recommended doses, but codeine crosses the placenta and may cause neonatal respiratory depression. Breastfeeding mothers should consult a healthcare professional, as codeine can be secreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements), and necessary import documentation.

Compared with non‑opioid NSAIDs such as ibuprofen, this combination adds an opioid component, offering stronger analgesia for pain that does not respond to NSAIDs alone. However, it carries additional risks of sedation, respiratory depression, and dependence, which are not typical of NSAIDs.

Paracetamol/Kodein Evolan should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets out of reach of children and do not use after the expiry date printed on the label.

The medication is supplied as oral tablets and should be taken with a full glass of water. It is usually taken with or without food, as directed by the prescriber, and the dosing schedule should be strictly followed to avoid accidental overdose.

The most serious risks include respiratory depression, especially when combined with other CNS depressants; severe allergic reactions such as anaphylaxis; and potential liver toxicity if paracetamol is taken in excess or in patients with pre‑existing liver disease.

Patients with severe hepatic impairment, uncontrolled respiratory conditions, known hypersensitivity to paracetamol or codeine, or those taking monoamine oxidase inhibitors should avoid this product. It is also contraindicated in children under the age limits set by local regulations for codeine‑containing medicines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.